Despite 30 years of study, there is no HIV-1 vaccine and, until recently, there was little hope
for a protective immunization. Renewed optimism in this area of research comes in part from …

Despite 30 years of effort, there is no effective vaccine for HIV-1. However, antibodies can
prevent HIV-1 infection in humanized mice and macaques when passively transferred. New …

In human medicine drug allergy is a well-established side-effect of the therapeutic use of
antibiotics, especially the β-lactams. Side-effects caused by macrolides are uncommon and …

Passive transfer of broadly neutralizing HIV antibodies can prevent infection, which suggests
that vaccines that elicit such antibodies would be protective. Thus far, however, few broadly …

During HIV-1 infection, antibodies are generated against the region of the viral gp120
envelope glycoprotein that binds CD4, the primary receptor for HIV-1. Among these antibodies, …

… To examine the memory antibody response to HIV, Scheid et al. cloned more than 500
antibodies from HIV-specific memory B cells from six HIV-infected patients with high serum titres …

HIV-1 immunotherapy with a combination of first generation monoclonal antibodies was
largely ineffective in pre-clinical and clinical settings and was therefore abandoned 1 , 2 , 3 . …

Broadly neutralizing antibodies (bNAbs) to HIV-1 can prevent infection and are therefore of
great importance for HIV-1 vaccine design. Notably, bNAbs are highly somatically mutated …

Broadly neutralizing HIV antibodies (bNAbs) can recognize carbohydrate-dependent epitopes
on gp120. In contrast to previously characterized glycan-dependent bNAbs that recognize …

Human antibodies to human immunodeficiency virus-1 (HIV-1) can neutralize a broad range
of viral isolates in vitro and protect non-human primates against infection 1 , 2 . Previous …